Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2008

View Archived Issues

Bentley reports positive results from phase II clinical study of Nasulin for type 2 diabetes

Clavis Pharma successfully completes Elacyt phase I clinical trial in hematology

Alocrest demonstrates preliminary efficacy and tolerability in phase I clinical trial

Primary endpoint met in second Avastin phase III study in metastatic breast cancer

Nektar restructures to become a therapeutics drug development organization

MorphoSys receives Dutch CTA approval to initiate a phase I clinical trial of MOR-103

New drugs for lipoprotein disorders reported in recent Auspex patent

Vaccinogen acquires rights to OncoVax vaccine to combat recurrence of colon cancer

Presidio and Numerate enter collaboration for novel small-molecule HCV inhibitors

Unigene initiates phase I/II clinical study of oral calcitonin for the treatment of osteoporosis

Diamyd submits answer to FDA question relating to phase III IND application for Diamyd

Dyax and sanofi-aventis enter agreements for fully human monoclonal antibody DX-2240

Schering-Plough and OraSure enter agreement for rapid point-of-care oral hepatitis C test

Horizon Therapeutics completes enrollment in two phase III clinical trials for HZT-501

Napo and Trine terminate license agreement for gastrointestinal product crofelemer

AEterna Zentaris commences dosing in phase II trial of cancer drug AEZS-108

Antares receives positive guidance from EMEA regarding registration of ATD Gel

Kamada to initiate phase II clinical trials of alpha-1 antitrypsin drug for bronchiectasis

Favorable preclinical profile of novel HIV integrase inhibitor INH-I001

Promising anti-HIV profile for novel NNRTIs developed at Ardea

Ono updates third quarter developments

Introgen and H. Lee Moffitt Cancer Center initiate phase II INGN-225 trial in small cell lung cancer

Taisho's novel CB2 receptor agonist shows analgesic activity in vivo

PF-232798 profiled at the CROI meeting

Recent Amgen patents disclose novel agents for autoimmune diseases

New treatment option for thrombotic disorders described in recent Bayer patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...